Jnj 42041935

AKB-4924 (kindly provided by Dr. Robert Shalwitz, Akebia Therapeutics, USA) was provided at a concentration of 2 mg/ml in 40% (v/v) aqueous 2-hydroxypropyl-beta cyclodextrin, 60% (v/v) 50 mM citrate buffer pH 5. 8-10 week old male BALB/c mice were randomised to receive either AKB-4924 at a dose of 5 mg/kg or 10 mg/kg, or vehicle control by daily subcutaneous injection starting 24 h after thrombus induction, based on previous reports in the literature demonstrating doses in this range stabilized HIF1α and reduced disease severity in a model of colitis [15, 23, 24] . JNJ-42041935 (kindly provided by Michael Rabinowitz, Johnson and Johnson, USA) was prepared in 20% (v/v) 2hydroxypropyl-beta cyclodextrin at a concentration of 3 mg/ml. 8-10 week old male BALB/c mice were randomised to receive either JNJ-42041935 at a dose of 35 mg/kg or vehicle control by daily intraperitoneal injection starting 24 h after thrombus induction based on previous reports in the literature demonstrating this dose is sufficient to induce HIF1α mediated erythropoietin expression and increase haemotocrit [16, 25, 26] .